Expertise in
20
conditions

Dr. Nicholas A. Butowski

Ucsf Medical Group Business Services
San Francisco, CA
Expertise in
20
conditions
Specialties:Neurosurgery | Neurology
Offers Telehealth
Expertise in
20
conditions
OverviewInsuranceLocationsClinical Research

Overview

Nicholas Butowski is a Neurosurgery specialist and a Neurologist in San Francisco, California. Dr. Butowski is highly rated in 20 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

His clinical research consists of co-authoring 132 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Neurology
Licenses
Neurological Surgery in CA
Hospital Affiliations
Ucsf Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

UCSF MEDICAL GROUP BUSINESS SERVICES
400 Parnassus Ave, San Francisco, CA 94143
415-476-1000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 17, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients with Recurrent Glioblastoma
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients with Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 02, 2024
Intervention Type: Biological
Study Drugs: PVSRIPO, Pembrolizumab
Study Phase: Phase 2
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug, Radiation
Study Drugs: Marizomib, Temozolomide
Study Phase: Phase 3
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
Enrollment Status: Active_not_recruiting
Publish Date: June 28, 2024
Intervention Type: Drug, Radiation
Study Drugs: BMX-001, Temozolomide
Study Phase: Phase 2
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Enrollment Status: Terminated
Publish Date: November 22, 2023
Intervention Type: Drug
Study Phase: Phase 3
Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice
Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice
Enrollment Status: Active_not_recruiting
Publish Date: November 03, 2023
A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in Recurrent WHO Grade IV Malignant Glioma Patients
A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in Recurrent WHO Grade IV Malignant Glioma Patients
Enrollment Status: Active_not_recruiting
Publish Date: September 28, 2023
Intervention Type: Biological
Study Drug: Oncolytic Polio/Rhinovirus Recombinant Vaccine
Study Phase: Phase 2
A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma
A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2023
Intervention Type: Drug
Study Drug: ONC201
Study Phase: Phase 2
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Biological, Other, Drug
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 1
An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Enrollment Status: Completed
Publish Date: October 24, 2022
Intervention Type: Drug
Study Phase: Phase 2
G-FORCE-1: An Open-Label Phase 1 Two Part Dose Escalation Trial of RRx-001 Concurrent With Radiation and Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas With Intact 1p/19q Chromosomes
G-FORCE-1: An Open-Label Phase 1 Two Part Dose Escalation Trial of RRx-001 Concurrent With Radiation and Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas With Intact 1p/19q Chromosomes
Enrollment Status: Completed
Publish Date: May 16, 2022
Intervention Type: Drug, Radiation
Study Drugs: RRx-001+TMZ+RT, Temozolomide
Study Phase: Phase 1
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain
A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain
Enrollment Status: Terminated
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 18 Less Clinical Trials

133 Total Publications

Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.
Journal: Neuro-oncology
Published: November 19, 2024
Similar Doctors
Expertise in
18
conditions
Dr. Jennie Taylor
Neurosurgery | Neurology
Expertise in
18
conditions
Dr. Jennie Taylor
Neurosurgery | Neurology

Ucsf Medical Group Business Services

400 Parnassus Ave, A808, 
San Francisco, CA 
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jennie Taylor is a Neurosurgery specialist and a Neurologist in San Francisco, California. Dr. Taylor is highly rated in 18 conditions, according to our data. Her top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

Expertise in
25
conditions
Dr. Praveen V. Mummaneni
Neurosurgery
Expertise in
25
conditions
Dr. Praveen V. Mummaneni
Neurosurgery

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Praveen Mummaneni is a Neurosurgery provider in San Francisco, California. Dr. Mummaneni is highly rated in 25 conditions, according to our data. His top areas of expertise are Spondylolisthesis, Cervical Myelopathy, Lordosis, Laminectomy, and Spinal Fusion.

Expertise in
51
conditions
Dr. Manish K. Aghi
Neurosurgery
Expertise in
51
conditions
Dr. Manish K. Aghi
Neurosurgery

Ucsf Medical Group Business Services

505 Parnassus Ave, M1490, 
San Francisco, CA 
 (0.1 mi)
415-472-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Manish Aghi is a Neurosurgery provider in San Francisco, California. Dr. Aghi is highly rated in 51 conditions, according to our data. His top areas of expertise are Pituitary Tumor, Hypothalamic Tumor, Glioma, Balloon Sinuplasty, and Awake Craniotomy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile